Asthenospermia (Asthenozoospermia)

Definition

• WHO 5th edition reference values: Lower limit (5th percentile) for progressive motility = 32% and for total motility (progressive + non-progressive) = 40%
• Values below these thresholds define asthenospermia
• Total asthenospermia = virtually no motile sperm; must be distinguished from necrospermia (dead sperm) using sperm vitality staining (e.g., hypoosmotic swelling test, eosin-nigrosin stain)

Causes

• Primary ciliary dyskinesia (Kartagener syndrome) - defects in dynein arms of the axoneme cause complete or near-complete immotility
• Y-chromosome microdeletions affecting spermatogenesis
• Mitochondrial dysfunction (mid-piece defects reduce ATP generation for flagellar motion)

• Antisperm antibodies (ASA) - disruption of the blood-testis barrier (by vasectomy, testis trauma, orchitis, cryptorchidism, varicocele) exposes sperm to the immune system; IgG and IgA antibodies bind sperm, particularly at the head or mid-piece, impairing motility. Tail-binding antibodies are less clinically significant
• Complete asthenospermia renders direct ASA assays (MAR test, immunobead test) impossible to perform

• Elevated leukocytes generate reactive oxygen species (ROS), which damage sperm membranes and mitochondria, impairing motility
• Associated with subclinical STIs (chlamydia, gonorrhea, mycoplasma), prostatitis, epididymitis

• Venous reflux increases scrotal temperature and oxidative stress, impairing sperm function; varicocele repair can improve motility

• Hypogonadism, hyperprolactinemia, thyroid disorders

• Cigarette smoking, alcohol, anabolic steroids, heat exposure, occupational toxins, certain medications (sulfasalazine, colchicine, nitrofurantoin)

• Retrograde ejaculation, prolonged abstinence

Diagnosis

Treatment

• Varicocele repair (microsurgical varicocelectomy) - improves motility in many men
• Antibiotics for confirmed genital tract infection (doxycycline, trimethoprim-sulfamethoxazole); treating leukocytospermia: doxycycline + frequent ejaculation (more than every 3 days)

• Antioxidants: Vitamins A, C, E; glutathione; omega-3 fatty acids - scavenge ROS, shown to improve motility in leukocytospermia
• Hormonal therapy: Gonadotropins (FSH) or antiestrogens (clomiphene, tamoxifen) in hypogonadotropic states or idiopathic infertility; a 2025 network meta-analysis suggests FSH and antiestrogens are comparably effective empirically
• Probiotics: Emerging evidence; a 2024 systematic review found some benefit on semen parameters

• Corticosteroid immunosuppression (rarely used due to side effects)
• Sperm washing + IUI
• IVF with ICSI - most effective when >50% sperm are antibody-bound or antibodies target the head/mid-piece

• IUI - for mild-moderate asthenospermia; sperm are washed and concentrated; pregnancy rates ~10-15%/cycle
• IVF with ICSI - indicated for severe male factor (motility <20%), complete asthenospermia, failed IUI, or immunologic infertility; a single motile sperm is all that is needed
• Sperm retrieval + ICSI - for complete asthenospermia / necrospermia when viable sperm are identified by vitality testing

• Avoid gonadotoxins (smoking, alcohol, anabolic steroids, heat)
• Avoid spermicidal lubricants (vegetable oils or olive oil are safe alternatives)
• Optimize coital timing (every other day around ovulation)
• Shorter abstinence periods (a 2024 systematic review found shorter abstinence improves motility outcomes)

Key Clinical Points

• Asthenospermia is one of the most common causes of male factor infertility; it rarely occurs in isolation and is often combined with oligospermia or teratozoospermia (OAT syndrome)
• Vitality staining is essential before diagnosing complete asthenospermia - necrospermia (dead sperm) requires a different workup
• Complete asthenospermia renders the MAR test and immunobead assay technically impossible - vitality testing first is mandatory
• COVID-19 infection has been associated with asthenospermia; a 2024 meta-analysis of 39 studies confirmed significant effects on semen motility, though recovery occurs in most men within 3 months
• No single semen parameter absolutely discriminates fertile from infertile - clinical context (bilateral testicular atrophy, elevated FSH, multiple abnormal analyses) guides management

Effect of Once-Weekly Vaping on Sperm Motility

The direct answer: no "safe" frequency threshold exists

What vaping aerosol contains that harms sperm

What the evidence shows

• A Danish cross-sectional study (Human Reproduction, 2020) found daily e-cigarette users had total sperm counts of 91 million vs. 147 million in non-users - a ~38% reduction. Motility was also impaired.
• A 2026 PMC review (Impact of lifestyle and environmental factors on fertility) confirmed that vaping disrupts the HPG axis and lowers sperm concentration and count in daily users.

• A 2025 retrospective study (Kim et al., Sci Rep, PMID 40610584) comparing 151 conventional cigarette smokers vs. 145 e-cigarette users in IVF found:
  • E-cigarette users had higher progressive sperm motility than conventional smokers (p=0.014)
  • E-cigarette users had a significantly higher live birth rate in IVF cycles
  • But both groups were still smokers - the comparison is against a more toxic baseline, not against non-users
• Conclusion: vaping is less harmful than daily cigarette smoking for sperm motility, but not equivalent to not vaping at all

• A July 2025 paper in Communications Biology (Cui et al.) using single-cell RNA sequencing showed nicotine exposure causes:
  • Reduced sperm concentration, progressive motility, and non-progressive motility
  • Disruption of the entire testicular microenvironment (Sertoli, Leydig cells, germ cells)
  • Epigenetic DNA methylation changes - some of which may persist beyond cessation
  • Partial but not complete recovery of sperm parameters after cessation (requires >1 full spermatogenic cycle = 74 days minimum)

• No human RCT exists for low-frequency vaping. The biology suggests harm scales with cumulative nicotine exposure and ROS burden.
• One vaping session delivers a bolus of ROS and nicotine. Sperm take ~74 days (one spermatogenesis cycle) to mature from stem cells. Repeated insults during that window accumulate.
• Once-weekly use represents ~14% of daily use exposure - a substantially lower burden, but not zero. The effects would likely be subclinical (not detectable on standard semen analysis) but may still affect sperm DNA integrity (sperm DNA fragmentation, or SDF), which standard motility assays do not measure.

What once-weekly vaping probably does and does not do

Reversibility

Bottom line

• There is no proven "safe" vaping frequency for sperm motility
• The main active harm - nicotine and ROS - is dose-dependent; lower frequency = lower risk, not zero risk
• Sperm DNA integrity (a more sensitive marker) may be affected even with infrequent use
• For anyone undergoing fertility evaluation or ART, cessation for at least 3 months before semen analysis is advisable to allow a full spermatogenic cycle to complete

Indian Population: Average Sperm Motility Analysis

Reference Values: Indian Men vs. WHO Standards

Sperm Motility - Indian Fertile Men

Sperm Motility - Indian Infertile Men

Southern India: 17-Year Single-Centre Data (2025)

Most Common Semen Abnormality in India: Asthenozoospermia

• Asthenozoospermia was the single most common semen abnormality: 23.4% of all infertile men
• Male factor subfertility accounted for 27.3% of all infertility cases
• Independent predictors of abnormal semen parameters (including low motility):

Temporal Trend: Is Indian Sperm Motility Declining?

Indian-Specific Factors Affecting Motility

• High ambient temperatures (especially in tropical climates) - scrotal hyperthermia impairs spermatogenesis
• Agricultural pesticide exposure (organophosphates, endosulfan) - documented in Kerala and other farming states
• Industrial pollutants (heavy metals in textile, leather, chemical workers)
• Air pollution - PM2.5 and cadmium exposure linked to reduced motility

• Tobacco use (bidis + cigarettes both): strongly associated with reduced motility (p < 0.001) - 2025 Oncoscience study, 278 Indian men
• Alcohol consumption: reduces motility and increases sperm DNA fragmentation
• BMI extremes: both underweight (common in lower-income groups) and overweight/obese men show lower motility
• Sedentary urban lifestyle

• Consanguineous marriages (common in South India) - higher prevalence of Y-chromosome microdeletions
• Higher rates of genital TB (GUTB) in India compared to Western populations - damages epididymis/vas, impairing motility

• The IM-FaST study identified prior COVID-19 as an independent predictor of abnormal semen parameters (p = 0.014), consistent with global data on SARS-CoV-2 and asthenozoospermia

Summary Table: Quick Reference for Indian Men

Clinical Interpretation

• Indian reference values for total motility (mean 66%, 5th percentile 49%) are broadly comparable to or slightly higher than WHO global norms in fertile men
• The lower 5th percentile for progressive motility (20%) is below the WHO threshold of 32% - meaning using WHO cutoffs directly on Indian populations may over-diagnose asthenospermia
• Population-specific reference ranges (as derived by Mishra et al.) should ideally be used when evaluating Indian patients
• Asthenozoospermia is the dominant semen abnormality in Indian infertile men (23.4%), making it the most clinically relevant parameter to assess